Previous 10 | Next 10 |
Summary I wanted to focus on an opportunity to acquire well-known big-cap names in the S&P 500 that, at this point, could provide "tech-like" returns. I attempt to explain these precipitous bear market rallies, and how we anticipate them. I also talk about a tactical shift...
Summary Biohaven's most valuable migraine-related assets were recently acquired by Pfizer for $11.6 billion. This has left a far smaller stub of cash and other pharmaceutical assets now trading as Biohaven that may be worth around $24/share, well above the current price. Inter...
Make it two days in a row of big gains for Biohaven Ltd. (NYSE: BHVN) . Shares of the drugmaker skyrocketed 47.7% on Wednesday as of the market close. On Tuesday, Biohaven stock jumped nearly 14% . The momentum is primarily due to the company's new beginning after being spun...
Shares of Biohaven Ltd. (NYSE: BHVN) were soaring 12.7% as of 11:23 a.m. ET on Tuesday after skyrocketing as much as 21.4% earlier in the day. The big gain came after Pfizer (NYSE: PFE) completed its acquisition of Biohaven Pharmaceutical on Monday. This transaction coul...
Biohaven Sets New Course with $258 Million in Cash, a Proven Team and Deep Pipeline to Continue its Journey to Advance Science for Patients PR Newswire Broad therapeutic research and development portfolio includes more than 13 clinical and pre-clinical programs with ...
Acquisition adds breakthrough calcitonin gene-related peptide portfolio, including NURTEC® ODT, to address needs of millions of migraine patients worldwide Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Compa...
Biohaven Pharmaceutical ( NYSE: BHVN ) said Thursday that its candidate for rare neuromuscular disease amyotrophic lateral sclerosis (ALS), verdiperstat did not meet the main goal in a pivotal Phase 2/3 trial after 24 weeks of treatment. A focused analysis from the HEALEY ...
Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial) PR Newswire NEW HAVEN, Conn. , Sept. 29, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) tod...
Biohaven Pharmaceutical Holding Company ( NYSE: BHVN ) has declared Sep. 26 as the record date for the previously announced spinoff of its subsidiary Biohaven Ltd., a condition to complete its buyout deal with Pfizer ( PFE ). Biohaven Ltd. will own certain clinical ass...
Biohaven Announces Record Date for Anticipated Spin-Off PR Newswire NEW HAVEN, Conn. , Sept. 18, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") today announced that it has set a record date of September 26, 2...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-07-20 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...